Real‐World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety‐Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024
Cancer Medicine · 2026
DOI: 10.1002/cam4.72223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Dominick Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California, USA. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
While overall survival for chronic myeloid leukemia (CML) at 5 years now exceeds 90% with modern tyrosine kinase inhibitor (TKI) therapies, disparities in management and outcomes persist among underserved populations. This study describes TKI treatment patterns and outcomes in a predominantly Hispanic, underserved CML cohort treated at Los Angeles County safety‐net hospitals.
Methods
We performed a retrospective chart review of 108 adult patients with CML who presented to Los Angeles County hospitals between 2015 and 2024. Data collected included demographics, comorbidities, treatment selection per line of therapy (LOT), and major molecular response (MMR; > 3‐log reduction) rates.
Results
The majority (58.3%) of patients were Hispanic, and most (59.2%) lived in zip codes with household incomes below the national average. The median age at diagnosis was 46 years old, and 82.4% of patients had comorbid conditions at diagnosis, including elevated BMI (67.5%), hypertension (28.7%), and diabetes (20.4%). By EUTOS score, 55.6% of patients were low‐risk, and 11.1% were high‐risk. Imatinib was the most common first‐line treatment for 64.8% of patients, followed by 31.5% with dasatinib. MMR was achieved in 44.4% of patients, while 43.5% of patients discontinued first‐line LOT due to medication intolerance. Overall, 56.5% of patients progressed to second LOT and 27% required third LOT.
Conclusions
Despite a younger median age at diagnosis, our patients had less favorable outcomes compared to previously published cohorts including lower rates of MMR with first‐line therapy, higher rates of toxicity, and needing more lines of therapy overall. These findings highlight the need for further investigation into the socioeconomic, biologic, and treatment‐access factors impacting outcomes in underserved patients with CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Torrance, California, USA.
- The Lundquist Research Institute, Torrance, California, USA.
ORCID-Profile: Dominick Zheng, Timothy Nold
Zitieren
APA
Zheng, D., Nold, T., Ramakrishnan, N., Kim, K., & Tomassetti, S. (2026). Real‐World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety‐Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024. Cancer Medicine. https://doi.org/10.1002/cam4.72223
Vancouver
Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real‐World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety‐Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024. Cancer Medicine. 2026. doi:10.1002/cam4.72223
BibTeX
@article{Zheng2026,
author = {Zheng, Dominick and Nold, Timothy and Ramakrishnan, Neeraj and Kim, Kailyn and Tomassetti, Sarah},
title = {Real‐World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety‐Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72223}
}
EUVIMED